Acetate- Versus Lactate-Buffered Crystalloids for Prevention of Post-ERCP Pancreatitis in Patients Without Access to Rectal NSAIDs: A Multicentre Double-Blind Randomized Trial.
United European Gastroenterol JSep 1, 2026
Woo Hyun Paik, Gunn Huh, Young Hoon Choi et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicentre double-blind randomized trial compared lactated Ringer's solution (LR) and acetate-buffered crystalloid (AC) for preventing post-ERCP pancreatitis (PEP) in 813 adults at moderate-to-high risk. PEP occurred in 12.4% of the LR group and 11.5% of the AC group, showing no significant difference (RR 0.93; P = 0.70).
Key findings
- PEP incidence was 12.4% in the LR group and 11.5% in the AC group.
- No severe PEP or fluid overload occurred in either group.
- Among asymptomatic patients at 4 hours, PEP occurred in 7.4%.
Why it matters
Understanding the effectiveness of different intravenous fluids in preventing post-ERCP pancreatitis is crucial for optimizing patient care, especially in settings where certain medications are unavailable.